Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn2+ in cognitively intact aged individuals with Alzheimer’s disease neuropathology
Background Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neu...
Saved in:
Published in | Molecular neurodegeneration Vol. 7; no. 1; p. 23 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central
28.05.2012
BMC |
Subjects | |
Online Access | Get full text |
ISSN | 1750-1326 1750-1326 |
DOI | 10.1186/1750-1326-7-23 |
Cover
Abstract | Background
Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neurofibrillary tangles). We term this group Non-Demented with AD Neuropathology or NDAN. The present study illustrates one putative resistance mechanism involved in NDAN cases which may suggest targets for the effective treatment of AD.
Results
Here we describe the localization of Aβ oligomers at the postsynapse in hippocampi from AD cases. Notably, however, we also found that while present in soluble fractions, Aβ oligomers are absent from hippocampal postsynapses in NDAN cases. In addition, levels of phosphorylated (active) CREB, a transcription factor important for synaptic plasticity, are normal in NDAN individuals, suggesting that their synapses are functionally intact. Analysis of Zn
2+
showed that levels were increased in both soluble fractions and synaptic vesicles in AD hippocampi, paralleled by a decrease of expression of the synaptic vesicle Zn
2+
transporter, ZnT3. Conversely, in NDAN individuals, levels of Zn
2+
in soluble fractions were significantly lower than in AD, whereas in synaptic vesicles the levels of Zn
2+
were similar to AD, but accompanied by preserved expression of the ZnT3.
Conclusions
Taken together, these data illustrate that despite substantial AD neuropathology, Aβ oligomers, and increased synaptic vesicle Zn
2+
, susceptible brain tissue in these aged NDAN individuals features, as compared to symptomatic AD subjects, significantly lower total Zn
2+
levels and no association of Aβ oligomers with the postsynapse, which collectively may promote the maintenance of intact cognitive function. |
---|---|
AbstractList | Background
Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neurofibrillary tangles). We term this group Non-Demented with AD Neuropathology or NDAN. The present study illustrates one putative resistance mechanism involved in NDAN cases which may suggest targets for the effective treatment of AD.
Results
Here we describe the localization of Aβ oligomers at the postsynapse in hippocampi from AD cases. Notably, however, we also found that while present in soluble fractions, Aβ oligomers are absent from hippocampal postsynapses in NDAN cases. In addition, levels of phosphorylated (active) CREB, a transcription factor important for synaptic plasticity, are normal in NDAN individuals, suggesting that their synapses are functionally intact. Analysis of Zn
2+
showed that levels were increased in both soluble fractions and synaptic vesicles in AD hippocampi, paralleled by a decrease of expression of the synaptic vesicle Zn
2+
transporter, ZnT3. Conversely, in NDAN individuals, levels of Zn
2+
in soluble fractions were significantly lower than in AD, whereas in synaptic vesicles the levels of Zn
2+
were similar to AD, but accompanied by preserved expression of the ZnT3.
Conclusions
Taken together, these data illustrate that despite substantial AD neuropathology, Aβ oligomers, and increased synaptic vesicle Zn
2+
, susceptible brain tissue in these aged NDAN individuals features, as compared to symptomatic AD subjects, significantly lower total Zn
2+
levels and no association of Aβ oligomers with the postsynapse, which collectively may promote the maintenance of intact cognitive function. Abstract Background Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neurofibrillary tangles). We term this group Non-Demented with AD Neuropathology or NDAN. The present study illustrates one putative resistance mechanism involved in NDAN cases which may suggest targets for the effective treatment of AD. Results Here we describe the localization of Aβ oligomers at the postsynapse in hippocampi from AD cases. Notably, however, we also found that while present in soluble fractions, Aβ oligomers are absent from hippocampal postsynapses in NDAN cases. In addition, levels of phosphorylated (active) CREB, a transcription factor important for synaptic plasticity, are normal in NDAN individuals, suggesting that their synapses are functionally intact. Analysis of Zn2+ showed that levels were increased in both soluble fractions and synaptic vesicles in AD hippocampi, paralleled by a decrease of expression of the synaptic vesicle Zn2+ transporter, ZnT3. Conversely, in NDAN individuals, levels of Zn2+ in soluble fractions were significantly lower than in AD, whereas in synaptic vesicles the levels of Zn2+ were similar to AD, but accompanied by preserved expression of the ZnT3. Conclusions Taken together, these data illustrate that despite substantial AD neuropathology, Aβ oligomers, and increased synaptic vesicle Zn2+, susceptible brain tissue in these aged NDAN individuals features, as compared to symptomatic AD subjects, significantly lower total Zn2+ levels and no association of Aβ oligomers with the postsynapse, which collectively may promote the maintenance of intact cognitive function. Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neurofibrillary tangles). We term this group Non-Demented with AD Neuropathology or NDAN. The present study illustrates one putative resistance mechanism involved in NDAN cases which may suggest targets for the effective treatment of AD. Here we describe the localization of Aβ oligomers at the postsynapse in hippocampi from AD cases. Notably, however, we also found that while present in soluble fractions, Aβ oligomers are absent from hippocampal postsynapses in NDAN cases. In addition, levels of phosphorylated (active) CREB, a transcription factor important for synaptic plasticity, are normal in NDAN individuals, suggesting that their synapses are functionally intact. Analysis of Zn2+ showed that levels were increased in both soluble fractions and synaptic vesicles in AD hippocampi, paralleled by a decrease of expression of the synaptic vesicle Zn2+ transporter, ZnT3. Conversely, in NDAN individuals, levels of Zn2+ in soluble fractions were significantly lower than in AD, whereas in synaptic vesicles the levels of Zn2+ were similar to AD, but accompanied by preserved expression of the ZnT3. Taken together, these data illustrate that despite substantial AD neuropathology, Aβ oligomers, and increased synaptic vesicle Zn2+, susceptible brain tissue in these aged NDAN individuals features, as compared to symptomatic AD subjects, significantly lower total Zn2+ levels and no association of Aβ oligomers with the postsynapse, which collectively may promote the maintenance of intact cognitive function. Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neurofibrillary tangles). We term this group Non-Demented with AD Neuropathology or NDAN. The present study illustrates one putative resistance mechanism involved in NDAN cases which may suggest targets for the effective treatment of AD.BACKGROUNDEarly cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neurofibrillary tangles). We term this group Non-Demented with AD Neuropathology or NDAN. The present study illustrates one putative resistance mechanism involved in NDAN cases which may suggest targets for the effective treatment of AD.Here we describe the localization of Aβ oligomers at the postsynapse in hippocampi from AD cases. Notably, however, we also found that while present in soluble fractions, Aβ oligomers are absent from hippocampal postsynapses in NDAN cases. In addition, levels of phosphorylated (active) CREB, a transcription factor important for synaptic plasticity, are normal in NDAN individuals, suggesting that their synapses are functionally intact. Analysis of Zn2+ showed that levels were increased in both soluble fractions and synaptic vesicles in AD hippocampi, paralleled by a decrease of expression of the synaptic vesicle Zn2+ transporter, ZnT3. Conversely, in NDAN individuals, levels of Zn2+ in soluble fractions were significantly lower than in AD, whereas in synaptic vesicles the levels of Zn2+ were similar to AD, but accompanied by preserved expression of the ZnT3.RESULTSHere we describe the localization of Aβ oligomers at the postsynapse in hippocampi from AD cases. Notably, however, we also found that while present in soluble fractions, Aβ oligomers are absent from hippocampal postsynapses in NDAN cases. In addition, levels of phosphorylated (active) CREB, a transcription factor important for synaptic plasticity, are normal in NDAN individuals, suggesting that their synapses are functionally intact. Analysis of Zn2+ showed that levels were increased in both soluble fractions and synaptic vesicles in AD hippocampi, paralleled by a decrease of expression of the synaptic vesicle Zn2+ transporter, ZnT3. Conversely, in NDAN individuals, levels of Zn2+ in soluble fractions were significantly lower than in AD, whereas in synaptic vesicles the levels of Zn2+ were similar to AD, but accompanied by preserved expression of the ZnT3.Taken together, these data illustrate that despite substantial AD neuropathology, Aβ oligomers, and increased synaptic vesicle Zn2+, susceptible brain tissue in these aged NDAN individuals features, as compared to symptomatic AD subjects, significantly lower total Zn2+ levels and no association of Aβ oligomers with the postsynapse, which collectively may promote the maintenance of intact cognitive function.CONCLUSIONSTaken together, these data illustrate that despite substantial AD neuropathology, Aβ oligomers, and increased synaptic vesicle Zn2+, susceptible brain tissue in these aged NDAN individuals features, as compared to symptomatic AD subjects, significantly lower total Zn2+ levels and no association of Aβ oligomers with the postsynapse, which collectively may promote the maintenance of intact cognitive function. |
ArticleNumber | 23 |
Author | Reese, Lindsay C Sadagoparamanujam, V-M Woltjer, Randall L Bjorklund, Nicole L Ghirardi, Valeria Taglialatela, Giulio |
AuthorAffiliation | 1 Department of Neuroscience and Cell Biology, Galveston, TX, 77555, USA 3 Department of Pathology, Oregon Health & Science University, Portland, OR, 97201, USA 2 Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX, 77555, USA |
AuthorAffiliation_xml | – name: 1 Department of Neuroscience and Cell Biology, Galveston, TX, 77555, USA – name: 2 Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX, 77555, USA – name: 3 Department of Pathology, Oregon Health & Science University, Portland, OR, 97201, USA |
Author_xml | – sequence: 1 givenname: Nicole L surname: Bjorklund fullname: Bjorklund, Nicole L organization: Department of Neuroscience and Cell Biology – sequence: 2 givenname: Lindsay C surname: Reese fullname: Reese, Lindsay C organization: Department of Neuroscience and Cell Biology – sequence: 3 givenname: V-M surname: Sadagoparamanujam fullname: Sadagoparamanujam, V-M organization: Department of Preventive Medicine and Community Health, University of Texas Medical Branch – sequence: 4 givenname: Valeria surname: Ghirardi fullname: Ghirardi, Valeria organization: Department of Neuroscience and Cell Biology – sequence: 5 givenname: Randall L surname: Woltjer fullname: Woltjer, Randall L organization: Department of Pathology, Oregon Health & Science University – sequence: 6 givenname: Giulio surname: Taglialatela fullname: Taglialatela, Giulio email: gtaglial@utmb.edu organization: Department of Neuroscience and Cell Biology |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22640423$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks1uEzEQx1eoiH7AlSPyEQlt64_d7OaCFFV8VKrEBS5crFl7duPIsYPtDQqnvkZPvAMPwkPwJDhJiVqknmzP_P-_8WjmtDhy3mFRvGT0nLF2csGampZM8EnZlFw8KU4OgaN79-PiNMYFpVVDaf2sOOZ8UtGKi5Pi56yL6BQS3xNYbqw3mvz-Rbw1g19iiAQSSXMkKx9T3DhYRSTgNAk4jBYSarKLJqPIV8ffEOOI8oMzyazRbvIzgUoEhiw0Tpu10SPYSL6bNCcz-2OOJlf5c3MbiTYRIdMdjsGvIM299cPmefG0zwZ8cXeeFV_ev_t8-bG8_vTh6nJ2XaqKT1IpaEt53WAHDHoquOaCTlvW0j5336DqaNv2IABUTau60VUltEbWNXXfY06Is-Jqz9UeFnIVzBLCRnowchfwYZAQcpcWZV2rBoDSTnS8Uoy3DCvaCtogqF6LOrPe7lmrsVuiVuhSAPsA-jDjzFwOfi1FRcW03QJe3wGC_zZiTHJpokJrwaEfo2SUt5Q1k3aapa_u1zoU-TfhLDjfC1TwMQbsDxJG5XaF5HZL5HZLZCN3huo_gzIJkvHbvxr7uO1ib4uZ7wYMcuHH4PLMHnP8BRjF3cY |
CitedBy_id | crossref_primary_10_3389_fncel_2021_660693 crossref_primary_10_1007_s00401_022_02526_0 crossref_primary_10_1001_jamaneurol_2023_3530 crossref_primary_10_1017_neu_2015_18 crossref_primary_10_1172_JCI64595 crossref_primary_10_1016_j_semcdb_2022_05_028 crossref_primary_10_1038_srep36772 crossref_primary_10_1038_s41582_022_00642_9 crossref_primary_10_3233_JAD_180179 crossref_primary_10_3389_fphar_2014_00085 crossref_primary_10_3389_fneur_2022_882635 crossref_primary_10_1038_s41598_017_15357_x crossref_primary_10_2139_ssrn_4200166 crossref_primary_10_1093_mtomcs_mfae053 crossref_primary_10_1111_jnc_13713 crossref_primary_10_3389_fncel_2015_00191 crossref_primary_10_3390_biomedicines10071743 crossref_primary_10_9729_AM_2012_42_4_200 crossref_primary_10_1007_s12035_020_01868_8 crossref_primary_10_1002_jnr_23777 crossref_primary_10_1111_jnc_13043 crossref_primary_10_3233_JAD_200716 crossref_primary_10_1016_j_cca_2017_11_009 crossref_primary_10_1007_s12263_013_0379_x crossref_primary_10_1016_j_neubiorev_2023_105246 crossref_primary_10_1016_j_pharmthera_2023_108398 crossref_primary_10_1038_s41467_021_22742_8 crossref_primary_10_1016_j_pneurobio_2015_03_003 crossref_primary_10_3389_fnmol_2022_1016559 crossref_primary_10_1111_bpa_13108 crossref_primary_10_1186_s13024_024_00719_7 crossref_primary_10_1007_s00018_020_03473_3 crossref_primary_10_1007_s11095_017_2267_3 crossref_primary_10_1016_j_pneurobio_2017_03_001 crossref_primary_10_1016_j_phymed_2025_156366 crossref_primary_10_1016_j_neubiorev_2017_06_006 crossref_primary_10_1038_s42003_023_05511_9 crossref_primary_10_1038_s41392_023_01679_y crossref_primary_10_1038_srep38187 crossref_primary_10_3390_jcm8050685 crossref_primary_10_1111_acel_12802 crossref_primary_10_1016_j_arr_2025_102711 crossref_primary_10_3389_fnins_2018_00037 crossref_primary_10_1038_s41380_022_01459_0 crossref_primary_10_1016_j_neurobiolaging_2014_06_015 crossref_primary_10_1038_s41598_024_66970_6 crossref_primary_10_1523_JNEUROSCI_0295_20_2020 crossref_primary_10_1523_JNEUROSCI_3307_17_2018 crossref_primary_10_1007_s10072_015_2352_5 crossref_primary_10_3233_JAD_210607 crossref_primary_10_3389_fnins_2024_1420322 crossref_primary_10_3389_fnagi_2014_00174 crossref_primary_10_1038_srep27812 crossref_primary_10_2337_db13_1954 crossref_primary_10_1016_j_ajpath_2015_09_018 crossref_primary_10_1152_physrev_00035_2014 crossref_primary_10_1155_2015_591563 crossref_primary_10_1016_j_celrep_2020_107900 crossref_primary_10_1093_brain_awab319 crossref_primary_10_1039_C4CS00138A crossref_primary_10_1371_journal_pone_0259335 crossref_primary_10_3389_fncel_2015_00464 crossref_primary_10_2139_ssrn_3519898 crossref_primary_10_3233_JAD_150065 crossref_primary_10_1007_s00401_024_02775_1 crossref_primary_10_1016_j_ebiom_2016_03_035 |
Cites_doi | 10.1523/JNEUROSCI.3432-04.2004 10.1016/S0143-4160(03)00140-4 10.1186/1750-1326-4-53 10.1212/WNL.54.1.105 10.1523/JNEUROSCI.3501-06.2007 10.1007/s00418-005-0787-0 10.1177/002215549904700211 10.1074/jbc.R600011200 10.1146/annurev.neuro.21.1.127 10.1016/S0006-8993(00)03196-6 10.1111/j.1471-4159.2006.04157.x 10.1021/ja076282l 10.1016/j.neurobiolaging.2010.01.010 10.1016/0022-3956(75)90026-6 10.1016/j.neurobiolaging.2007.05.005 10.1113/jphysiol.2005.103754 10.1111/j.1471-4159.2010.06643.x 10.1016/j.pharmthera.2005.11.004 10.1016/j.bbr.2008.06.001 10.1016/0028-3908(94)90152-X 10.1212/01.wnl.0000223644.08653.b5 10.1093/jn/130.5.1471S 10.1007/BF02796647 10.1523/JNEUROSCI.5980-08.2009 10.1096/fj.04-2370com 10.1007/BF00308809 10.1016/S0002-9440(10)65184-X 10.1126/science.1074069 10.1074/jbc.M100175200 10.1016/S0021-9258(17)32694-7 10.1016/j.bpj.2011.02.042 10.1097/NEN.0b013e3181772794 10.1038/nm1782 10.1002/syn.20683 10.1007/s00401-011-0910-3 10.1038/nature04533 10.1016/S0165-0270(97)00079-4 10.3233/JAD-2009-0992 10.1021/bi701112z 10.1073/pnas.0811698106 10.1074/jbc.271.24.14214 10.1523/JNEUROSCI.5255-09.2010 10.1212/WNL.41.4.479 10.1016/0896-6273(91)90272-2 10.1186/1750-1326-6-65 10.1093/jn/130.5.1484S 10.1126/science.8073293 10.1016/S0006-8993(99)02096-X 10.1038/308734a0 10.1002/jnr.22445 10.1016/S0896-6273(01)00450-0 10.1016/j.jneumeth.2008.05.003 10.4061/2011/971021 10.1074/jbc.M500997200 10.1016/S0022-510X(96)00203-1 10.1021/bi047611e 10.1016/j.jneumeth.2011.09.008 10.1111/j.1474-9726.2008.00434.x 10.1523/JNEUROSCI.1064-09.2009 10.3390/s8117428 10.1038/nn1372 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M 10.1212/01.wnl.0000341273.18141.64 10.1073/pnas.91.18.8378 10.1021/bi990205o 10.1016/0165-6147(91)90609-V |
ContentType | Journal Article |
Copyright | Bjorklund et al.; licensee BioMed Central Ltd 2012 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2012 Bjorklund et al.; licensee BioMed Central Ltd 2012 Bjorklund et al.; licensee BioMed Central Ltd |
Copyright_xml | – notice: Bjorklund et al.; licensee BioMed Central Ltd 2012 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2012 Bjorklund et al.; licensee BioMed Central Ltd 2012 Bjorklund et al.; licensee BioMed Central Ltd |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1186/1750-1326-7-23 |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals (Selected full-text) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 1750-1326 |
EndPage | 23 |
ExternalDocumentID | oai_doaj_org_article_55c7aa00b3b24c1281e408307eacfd35 PMC3403985 22640423 10_1186_1750_1326_7_23 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NINDS NIH HHS grantid: F31NS062558 – fundername: NINDS NIH HHS grantid: R01NS059901 – fundername: NIEHS NIH HHS grantid: T32 ES007254-20 – fundername: NIA NIH HHS grantid: P30AG008017 |
GroupedDBID | --- 0R~ 123 29M 2VQ 2WC 4.4 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 HH5 HMCUK HYE IAO IHR INH INR IPNFZ IPY ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RIG RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW ~8M AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c426t-3080257eba1af032d23098180f3267ecb088fa3aac50457d443dde1b75ffefa33 |
IEDL.DBID | M48 |
ISSN | 1750-1326 |
IngestDate | Wed Aug 27 01:32:51 EDT 2025 Thu Aug 21 18:33:59 EDT 2025 Thu Sep 04 16:41:00 EDT 2025 Thu Apr 03 07:00:57 EDT 2025 Tue Jul 01 01:59:01 EDT 2025 Thu Apr 24 22:51:17 EDT 2025 Sat Sep 06 07:29:28 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Alzheimer’s disease hippocampus asymptomatic, zinc, synaptic vesicle Aβ oligomers |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c426t-3080257eba1af032d23098180f3267ecb088fa3aac50457d443dde1b75ffefa33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/55c7aa00b3b24c1281e408307eacfd35 |
PMID | 22640423 |
PQID | 1028017689 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_55c7aa00b3b24c1281e408307eacfd35 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3403985 proquest_miscellaneous_1028017689 pubmed_primary_22640423 crossref_primary_10_1186_1750_1326_7_23 crossref_citationtrail_10_1186_1750_1326_7_23 springer_journals_10_1186_1750_1326_7_23 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2012-05-28 |
PublicationDateYYYYMMDD | 2012-05-28 |
PublicationDate_xml | – month: 05 year: 2012 text: 2012-05-28 day: 28 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Molecular neurodegeneration |
PublicationTitleAbbrev | Mol Neurodegeneration |
PublicationTitleAlternate | Mol Neurodegener |
PublicationYear | 2012 |
Publisher | BioMed Central BMC |
Publisher_xml | – name: BioMed Central – name: BMC |
References | S Lesne (334_CR10) 2006; 440 AG Henriques (334_CR64) 2010; 113 SA Amico-Ruvio (334_CR37) 2011; 100 CJ Frederickson (334_CR55) 2000; 130 GM Aldridge (334_CR66) 2008; 172 HM Abdul (334_CR21) 2009; 29 D Erten-Lyons (334_CR6) 2009; 72 LC Reese (334_CR12) 2008; 7 M Stoltenberg (334_CR58) 2005; 123 SS Mirra (334_CR60) 1991; 41 GM Shankar (334_CR20) 2008; 14 A Mathie (334_CR39) 2006; 111 WH Yu (334_CR33) 2001; 894 MS Green (334_CR46) 2000; 54 M Townsend (334_CR56) 2006; 572 A Alzheimer’s (334_CR1) 2010; 2010 A Poling (334_CR14) 2008; 193 RM Koffie (334_CR18) 2009; 106 MA Deibel (334_CR28) 1996; 143 NL Bjorklund (334_CR63) 2012; 203 334_CR24 MP Lambert (334_CR52) 2007; 100 H Braak (334_CR3) 1991; 82 Y Uchida (334_CR31) 1991; 7 PN Lacor (334_CR51) 2004; 24 AM Grabrucker (334_CR19) 2011; 6 KH Lim (334_CR43) 2007; 46 AI Bush (334_CR45) 1994; 269 KT Dineley (334_CR16) 2010; 88 MA Riudavets (334_CR7) 2007; 28 N Beyer (334_CR30) 2009; 4 SY Assaf (334_CR35) 1984; 308 RJ Cousins (334_CR34) 2006; 281 G Danscher (334_CR27) 1997; 76 TJ Montine (334_CR9) 2012; 123 JP Cleary (334_CR11) 2005; 8 SD O’Shea (334_CR15) 2008; 8 J Naslund (334_CR48) 1994; 91 D Iacono (334_CR8) 2008; 67 AI Bush (334_CR44) 1994; 265 LF Lue (334_CR5) 1999; 155 MA Lovell (334_CR23) 2009; 16 D Religa (334_CR29) 2006; 67 DJ Selkoe (334_CR49) 2002; 298 RA Colvin (334_CR36) 2000; 130 MF Folstein (334_CR61) 1975; 12 SW Suh (334_CR59) 2000; 852 NL Harrison (334_CR38) 1994; 33 JW Karr (334_CR41) 2005; 44 HJ Romijn (334_CR62) 1999; 47 H Bito (334_CR53) 2003; 34 PA Adlard (334_CR32) 2010; 30 NW Alcock (334_CR67) 1987; 13 PN Lacor (334_CR17) 2007; 27 GR Phillips (334_CR50) 2001; 32 D Noy (334_CR25) 2008; 130 J Hardy (334_CR2) 1991; 12 A Deshpande (334_CR26) 2009; 29 AJ Silva (334_CR57) 1998; 21 CC Curtain (334_CR40) 2001; 276 Q Wang (334_CR65) 2005; 19 BKY Bitanihirwe (334_CR54) 2009; 63 PL Kramer (334_CR4) 2011; 32 A Demuro (334_CR13) 2005; 280 CA McLean (334_CR47) 1999; 46 AN Moore (334_CR22) 1996; 271 S-T Liu (334_CR42) 1999; 38 |
References_xml | – volume: 2010 start-page: 6 year: 2010 ident: 334_CR1 publication-title: Alzheimer’s & Dementia – volume: 24 start-page: 10191 year: 2004 ident: 334_CR51 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.3432-04.2004 – volume: 34 start-page: 425 year: 2003 ident: 334_CR53 publication-title: Cell Calcium doi: 10.1016/S0143-4160(03)00140-4 – volume: 4 start-page: 53 year: 2009 ident: 334_CR30 publication-title: Mol Neurodegener doi: 10.1186/1750-1326-4-53 – volume: 54 start-page: 105 year: 2000 ident: 334_CR46 publication-title: Neurology doi: 10.1212/WNL.54.1.105 – volume: 27 start-page: 796 year: 2007 ident: 334_CR17 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.3501-06.2007 – volume: 123 start-page: 605 year: 2005 ident: 334_CR58 publication-title: Histochem Cell Biol doi: 10.1007/s00418-005-0787-0 – volume: 47 start-page: 229 year: 1999 ident: 334_CR62 publication-title: J Histochem Cytochem doi: 10.1177/002215549904700211 – volume: 281 start-page: 24085 year: 2006 ident: 334_CR34 publication-title: J Biol Chem doi: 10.1074/jbc.R600011200 – volume: 21 start-page: 127 year: 1998 ident: 334_CR57 publication-title: Annu Rev Neurosci doi: 10.1146/annurev.neuro.21.1.127 – volume: 894 start-page: 37 year: 2001 ident: 334_CR33 publication-title: Brain Res doi: 10.1016/S0006-8993(00)03196-6 – volume: 100 start-page: 23 year: 2007 ident: 334_CR52 publication-title: J Neurochem doi: 10.1111/j.1471-4159.2006.04157.x – volume: 130 start-page: 1376 year: 2008 ident: 334_CR25 publication-title: J Am Chem Soc doi: 10.1021/ja076282l – volume: 32 start-page: 2113 year: 2011 ident: 334_CR4 publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2010.01.010 – volume: 12 start-page: 189 year: 1975 ident: 334_CR61 publication-title: J Psychiatr Res doi: 10.1016/0022-3956(75)90026-6 – volume: 28 start-page: 1484 year: 2007 ident: 334_CR7 publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2007.05.005 – volume: 572 start-page: 477 year: 2006 ident: 334_CR56 publication-title: J Physiol doi: 10.1113/jphysiol.2005.103754 – volume: 113 start-page: 761 year: 2010 ident: 334_CR64 publication-title: J Neurochem doi: 10.1111/j.1471-4159.2010.06643.x – volume: 111 start-page: 567 year: 2006 ident: 334_CR39 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2005.11.004 – volume: 193 start-page: 230 year: 2008 ident: 334_CR14 publication-title: Behavioural brain research doi: 10.1016/j.bbr.2008.06.001 – volume: 33 start-page: 935 year: 1994 ident: 334_CR38 publication-title: Neuropharmacology doi: 10.1016/0028-3908(94)90152-X – volume: 67 start-page: 69 year: 2006 ident: 334_CR29 publication-title: Neurology doi: 10.1212/01.wnl.0000223644.08653.b5 – volume: 130 start-page: 1471S year: 2000 ident: 334_CR55 publication-title: J Nutr doi: 10.1093/jn/130.5.1471S – volume: 13 start-page: 363 year: 1987 ident: 334_CR67 publication-title: Biol Trace Elem Res doi: 10.1007/BF02796647 – volume: 29 start-page: 4004 year: 2009 ident: 334_CR26 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.5980-08.2009 – volume: 19 start-page: 869 year: 2005 ident: 334_CR65 publication-title: FASEB J doi: 10.1096/fj.04-2370com – volume: 82 start-page: 239 year: 1991 ident: 334_CR3 publication-title: Acta Neuropathol doi: 10.1007/BF00308809 – volume: 155 start-page: 853 year: 1999 ident: 334_CR5 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)65184-X – volume: 298 start-page: 789 year: 2002 ident: 334_CR49 publication-title: Science doi: 10.1126/science.1074069 – volume: 276 start-page: 20466 year: 2001 ident: 334_CR40 publication-title: J Biol Chem doi: 10.1074/jbc.M100175200 – volume: 269 start-page: 12152 year: 1994 ident: 334_CR45 publication-title: J Biol Chem doi: 10.1016/S0021-9258(17)32694-7 – volume: 100 start-page: 1910 year: 2011 ident: 334_CR37 publication-title: Biophys J doi: 10.1016/j.bpj.2011.02.042 – volume: 67 start-page: 578 year: 2008 ident: 334_CR8 publication-title: J Neuropathol Exp Neurol doi: 10.1097/NEN.0b013e3181772794 – volume: 14 start-page: 837 year: 2008 ident: 334_CR20 publication-title: Nat Med doi: 10.1038/nm1782 – volume: 63 start-page: 1029 year: 2009 ident: 334_CR54 publication-title: Synapse doi: 10.1002/syn.20683 – volume: 123 start-page: 1 year: 2012 ident: 334_CR9 publication-title: Acta Neuropathol doi: 10.1007/s00401-011-0910-3 – volume: 440 start-page: 352 year: 2006 ident: 334_CR10 publication-title: Nature doi: 10.1038/nature04533 – volume: 76 start-page: 53 year: 1997 ident: 334_CR27 publication-title: J Neurosci Methods doi: 10.1016/S0165-0270(97)00079-4 – volume: 16 start-page: 471 year: 2009 ident: 334_CR23 publication-title: J Alzheimer’s Dis doi: 10.3233/JAD-2009-0992 – volume: 46 start-page: 13523 year: 2007 ident: 334_CR43 publication-title: Biochemistry doi: 10.1021/bi701112z – volume: 106 start-page: 4012 year: 2009 ident: 334_CR18 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0811698106 – volume: 271 start-page: 14214 year: 1996 ident: 334_CR22 publication-title: J Biol Chem doi: 10.1074/jbc.271.24.14214 – volume: 30 start-page: 1631 year: 2010 ident: 334_CR32 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.5255-09.2010 – volume: 41 start-page: 479 year: 1991 ident: 334_CR60 publication-title: Neurology doi: 10.1212/WNL.41.4.479 – volume: 7 start-page: 337 year: 1991 ident: 334_CR31 publication-title: Neuron doi: 10.1016/0896-6273(91)90272-2 – volume: 6 start-page: 65 year: 2011 ident: 334_CR19 publication-title: Mol Neurodegener doi: 10.1186/1750-1326-6-65 – volume: 130 start-page: 1484S year: 2000 ident: 334_CR36 publication-title: J Nutr doi: 10.1093/jn/130.5.1484S – volume: 265 start-page: 1464 year: 1994 ident: 334_CR44 publication-title: Science doi: 10.1126/science.8073293 – volume: 852 start-page: 274 year: 2000 ident: 334_CR59 publication-title: Brain Res doi: 10.1016/S0006-8993(99)02096-X – volume: 308 start-page: 734 year: 1984 ident: 334_CR35 publication-title: Nature doi: 10.1038/308734a0 – volume: 88 start-page: 2923 year: 2010 ident: 334_CR16 publication-title: J Neurosci Res doi: 10.1002/jnr.22445 – volume: 32 start-page: 63 year: 2001 ident: 334_CR50 publication-title: Neuron doi: 10.1016/S0896-6273(01)00450-0 – volume: 172 start-page: 250 year: 2008 ident: 334_CR66 publication-title: J Neurosci Methods doi: 10.1016/j.jneumeth.2008.05.003 – ident: 334_CR24 doi: 10.4061/2011/971021 – volume: 280 start-page: 17294 year: 2005 ident: 334_CR13 publication-title: J Biol Chem doi: 10.1074/jbc.M500997200 – volume: 143 start-page: 137 year: 1996 ident: 334_CR28 publication-title: J Neurol Sci doi: 10.1016/S0022-510X(96)00203-1 – volume: 44 start-page: 5478 year: 2005 ident: 334_CR41 publication-title: Biochemistry doi: 10.1021/bi047611e – volume: 203 start-page: 146 year: 2012 ident: 334_CR63 publication-title: J Neurosci Methods doi: 10.1016/j.jneumeth.2011.09.008 – volume: 7 start-page: 824 year: 2008 ident: 334_CR12 publication-title: Aging Cell doi: 10.1111/j.1474-9726.2008.00434.x – volume: 29 start-page: 12957 year: 2009 ident: 334_CR21 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.1064-09.2009 – volume: 8 start-page: 7428 year: 2008 ident: 334_CR15 publication-title: Sensors doi: 10.3390/s8117428 – volume: 8 start-page: 79 year: 2005 ident: 334_CR11 publication-title: Nat Neurosci doi: 10.1038/nn1372 – volume: 46 start-page: 860 year: 1999 ident: 334_CR47 publication-title: Ann Neurol doi: 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M – volume: 72 start-page: 354 year: 2009 ident: 334_CR6 publication-title: Neurology doi: 10.1212/01.wnl.0000341273.18141.64 – volume: 91 start-page: 8378 year: 1994 ident: 334_CR48 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.91.18.8378 – volume: 38 start-page: 9373 year: 1999 ident: 334_CR42 publication-title: Biochemistry doi: 10.1021/bi990205o – volume: 12 start-page: 383 year: 1991 ident: 334_CR2 publication-title: Trends Pharmacol Sci doi: 10.1016/0165-6147(91)90609-V |
SSID | ssj0047005 |
Score | 2.2577424 |
Snippet | Background
Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the... Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses.... Abstract Background Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers... |
SourceID | doaj pubmedcentral proquest pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 23 |
SubjectTerms | Aged, 80 and over Alzheimer Disease - metabolism Alzheimer Disease - pathology Alzheimer’s disease Amyloid beta-Peptides - metabolism asymptomatic, zinc, synaptic vesicle Aβ oligomers Biomedical and Life Sciences Biomedicine Blotting, Western Cognition Disorders - metabolism Cognition Disorders - pathology Female hippocampus Hippocampus - metabolism Hippocampus - pathology Humans Immunohistochemistry Male Molecular Medicine Neurology Neurosciences Research Article Synapses - metabolism Synapses - pathology Zinc - metabolism |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQT1wQUH7CnwYJARKymo0d2zkuiKpCghOVKi6W7dg00jZZNelhOfEanHgHHoSH4EkYO9mIBSouHONY8s-M58cz_oaQJ1YIXzFnqaxcoNwJRU0dFBXcVZWzqHIT2PPbd-LomL85KU9-KfUVc8JGeOBx4w7K0klj8twyW3AX4z6eo9mQS5QYoWYJvTSv8q0zNcpgLvOUvIi6Mafob4kJrnGhxMHcRiUt2I46Sqj9fzM1_8yY_C1smrTR4XVybTIjYTlO_wa54tubZH_Zogt9toGnkBI70435Pvm6tH08v9AFMGfooDc1fP8G3ar52MVbazADoBkI664f-k1r1r0H09ZwPpap9zWkVhwJPrTFC2hamJOOVhv8HIwbAOVSDc38vKuHeMMLy9WnU9_gKD8-f-lhigZBAtGMtZDTDG-R48PX718d0akuA3WozwfK4vvcUnprFibkrKjRjanim_GAuyo9UlipYJgxrkSDUdacMxSiCyvLEDz-YLfJXtu1_i4Br1yQPEYfK8uDMEpZtDgWlStUaRfeZIRuyaPdBFoea2esdHJelNCRnDqSU0tdsIw8m_uvR7iOS3u-jNSee0WY7dSAzKcn5tP_Yr6MPN7yisZjGWMtpvXdRa-j3YbCTqgqI3dG3pmHim-XYzpSRuQOV-3MZfdP25wm6G_Gc1YpHPf5lv_0JHP6S9Z573-s8z65ioZiEbMmCvWA7A3nF_4hGmODfZTO3U_SCTP0 priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELagXLggoPyEPw0SAiRkkcSO7RyXFVWFBCcqVVws27FppG2yatLDcuI1OPEOPAgPwZMw9mZXLKUSx9iO7GTGM994fkzIMyuEr5mzVNYuUO6EoqYJigru6tpZVLmp2PP7D-LwiL87ro6nANmYC_On_75Q4jVqt5yixSSopCW7Sq5VKHQjJ8_FfCNxuURWmgoyXnxnR-Gkuvz_ApMXYyL_cowmfXNwk9yYgCLM1pS9Ra747jbZn3VoJJ-u4Dmk0M10Jr5Pvs_sEHco9AHMKZrgbQM_f0C_aD_38VwazAgI9GDZD-Ow6sxy8GC6Bs7WF9H7BlIrzgSfuvIVtB1sw4oWK3wcjRsBJU8D7TaBa4B4hguzxZcT3-Isv75-G2Dy90AqkxlvO04rvEOODt5-nB_S6eYF6lBjj5TFDNxKemsKE3JWNmio1DErPOBflR5pqFQwzBhXISSUDecMxWRhZRWCxw52l-x1fefvE_DKBcmjf7G2PAijlEVMUdSuVJUtvMkI3ZBHu6ksebwdY6GTeaKEjuTUkZxa6pJl5MV2_HJdkOPSkW8itbejYiHt1ID8pad9qavKSWPy3DJbchfdip4jKs0lKqTQsCojTze8onHjRW-K6Xx_PuiIzFCcCVVn5N6ad7ZTxezkGHCUEbnDVTtr2e3p2pNU3JvxnNUK53254T89SZXhku988P9DH5LrCPjKGP1Qqkdkbzw7948RVI32SdpRvwERiiB0 priority: 102 providerName: Springer Nature |
Title | Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn2+ in cognitively intact aged individuals with Alzheimer’s disease neuropathology |
URI | https://link.springer.com/article/10.1186/1750-1326-7-23 https://www.ncbi.nlm.nih.gov/pubmed/22640423 https://www.proquest.com/docview/1028017689 https://pubmed.ncbi.nlm.nih.gov/PMC3403985 https://doaj.org/article/55c7aa00b3b24c1281e408307eacfd35 |
Volume | 7 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELZoe-GCgPKTAqtBQoCEAtnYiZ0DQumqVbUSFQJWWnGJbMdpI22TZZNKLCdegxPvwIPwEDwJY282aGkrcYriOHLimfF84xnPEPJExbFJqFY-T3ThMx0LX-aF8GOmk0QrVLku2fPb4_howsbTaPo3_qmbwOZS087Wk5osZi-_fF6-QYF_7QRexK9QAwY-WlWxz_2QbpEd5yuyYXys9ygwHrhwxr5vl8Dx4vsbCsrl8b8MfF6MofzHker00-FNcqMDlpCuOOEWuWaq22Q3rdCoPlvCU3Chnm4PfZf8SFVjJRrqAuQZmuxlDr9-Qj0rT2q7jw2yBQSGMK-btllWct4YkFUOi1XhepODa8WR4FMVvoCygj4MabbE21bqFnClyqHsD3w1YPd8IZ19PTUljvL72_cGOv8QuLSatjqy-8I7ZHJ48HF05HeVGnyNGr71qT2xG3Gj5FAWAQ1zNGwSe4q8wFnlBmkuRCGplDpCCMlzxiguq0PFo6Iw-IDeJdtVXZn7BIzQBWfWH5koVsRSCIUYZJjoUERqaKRH_DV5Mt2lMbfVNGaZM2dEnFlyZpacGc9C6pFnff_5KoHHlT33LbX7XjbxtmuoFydZJ8dZFGkuZRAoqkKmrRvSMESxAUcFVuQ08sjjNa9kKKjW-yIrU583mUVyuPzFIvHIvRXv9EPZ08w2QMkjfIOrNr5l80lVnrpk4JQFNBE47vM1_2VrIbriP_f-e0YekOuID0MbLBGKh2S7XZybR4jBWjUgW3zKB2QnTccfxnjdPzh-9x5bR_Fo4PY1Bk78_gC_fTZC |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELagHOCCgPKz_A4SAiQUNYkd2zkuK6oF2p5aqeJi2Y5NI22TVZMelhOvwYl34EF4CJ6EsTe7YimVOCZx5OzOeOYbz8xnQl4Yzl1JrUlEaX3CLJeJrrxMOLNlaQ263Ej2vH_Ap0fsw3FxPBTIhl6YP_P3meQ76N3SBCMmnogkp1fJtZC1DBz5Ez5ZWVwmUJUGQsaL72w4nMjL_y8webEm8q_EaPQ3u7fIzQEowngp2dvkimvukO1xg0Hy6QJeQizdjHvi2-T72HRhhULrQZ9iCF5X8PMHtLP6cxv2pUH3gEAP5m3Xd4tGzzsHuqngbHkQvasg3sWZ4FOTv4G6gXVZ0WyBl722PaDlqaBeN3B1EPZwYTz7cuJqnOXX128dDPkeiDSZ4bTj-IV3ydHuu8PJNBlOXkgseuw-oaEDtxDO6Ez7lOYVBipl6Ar3-K8KhzKU0muqtS0QEoqKMYpmMjOi8N7hA3qPbDVt4x4QcNJ6wUJ-sTTMcy2lQUyRlTaXhcmcHpFkJR5lB1rycDrGTMXwRHIVxKmCOJVQOR2RV-vx8yUhx6Uj3wZpr0cFIu14A_VLDetSFYUVWqepoSZnNqQVHUNUmgp0SL6ixYg8X-mKwoUXsim6ce15pwIyQ3PGZTki95e6s54qdCeHgqMRERtatfEtm0-a-iSSe1OW0lLivK9X-qcGq9Jd8jsf_v_QZ-T69HB_T-29P_j4iNxA8JeHSohcPiZb_dm5e4IAqzdP4-r6DcouI2M |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELZKKyEuqFCgS_kZJARIKGo2TmJH4hJ-VmWBCgkqVVws27HbSNtktUkPy4nX4MQ78CA8BE_C2ElWWkoljnEcOcn8e2Y-E_JYpanJqFYBy7QNYp3yQBaWB2mss0wrNLke7PnDYXpwFE-Pk-MN8mLohfHV7kNKsutpcChNVbs_L2wn4jzdR5sXBhhHpQELInqFbPEkyzD02srz6afpoIljhizWAzVefGrNEHm8_n85mRdrJf9KmHo7NNkm13sHEvKO4jfIhqlukp28wuD5bAlPwJd0-r3yHfIjV42TXKgtyDMMzcsCfv2Eelae1G6_GmQL6ADCvG7aZlnJeWNAVgUsugPqTQF-FFeCL1X0HMoKVuVGsyVetlK3gBqpgHLV2NWA29uFfPb11JS4yu9v3xvo80Dg4TPdKcj-DW-Ro8mbz68Ogv5EhkCjJW8D6jpzE2aUHEsb0qjAACZz3eIW_yozSFvOraRS6gRdRVbEMUX1OVYssdbgDXqbbFZ1ZXYJGK4ti13eMVOxTSXnCn2NcaYjnqixkSMSDOQRuocrd6dmzIQPW3gqHDmFI6dgIqIj8nQ1f94BdVw686Wj9mqWA9j2A_XiRPTyKpJEMynDUFEVxdqlG02M3mrI0FDZgiYj8mjgFYEC6bIssjL1eSOcx4ZqLuXZiNzpeGe1lOtadoVII8LWuGrtXdbvVOWpB_2mcUgzjus-G_hP9NqmueQ77_7_1Ifk6sfXE_H-7eG7PXINfcLIFUhE_B7ZbBfn5j76Xa160IvXHyw_LSE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Absence+of+amyloid+%CE%B2+oligomers+at+the+postsynapse+and+regulated+synaptic+Zn2%2B+in+cognitively+intact+aged+individuals+with+Alzheimer%E2%80%99s+disease+neuropathology&rft.jtitle=Molecular+neurodegeneration&rft.au=Bjorklund%2C+Nicole+L&rft.au=Reese%2C+Lindsay+C&rft.au=Sadagoparamanujam%2C+V-M&rft.au=Ghirardi%2C+Valeria&rft.date=2012-05-28&rft.issn=1750-1326&rft.eissn=1750-1326&rft.volume=7&rft.issue=1&rft_id=info:doi/10.1186%2F1750-1326-7-23&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_1750_1326_7_23 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1326&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1326&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1326&client=summon |